
Opinion|Videos|January 20, 2025
Patient Selection for Teplizumab and Infusion Process
Panelists discuss how patient selection for teplizumab therapy requires careful screening for autoantibody positivity and preserved C-peptide function, followed by a 14-day outpatient infusion process that needs close monitoring for cytokine release syndrome and other potential adverse effects.
Advertisement
Episodes in this series

Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Phase 3 Data Support Oral Orforglipron for Weight Maintenance After GLP-1–Based Weight Loss
2
FDA Approves Abbott Volt Pulsed Field Ablation System for Treatment of Atrial Fibrillation
3
Needle Anxiety and Injection Site Pain: Evidence-Based Strategies for Patient Counseling on Injectable PrEP
4
Colonoscopy May be the Gold Standard, But Now It's a CRC Screening Bottleneck, Says Mark Fendrick, MD
5















































































































































































































































































